ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Ann Thorac Surg 2008;86:1753-1761. doi:10.1016/j.athoracsur.2008.06.027
© 2008 The Society of Thoracic Surgeons

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Abel Gómez-Caro
Alberto Rodríguez
Josep Maria Gimferrer
Axel Haverich
Wolfgang Harringer
Jose Louis Pomar
Paolo Macchiarini
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gómez-Caro, A.
Right arrow Articles by Macchiarini, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gómez-Caro, A.
Right arrow Articles by Macchiarini, P.
Related Collections
Right arrow Lung - cancer
Right arrow Great vessels


Original Articles: General Thoracic

Cryopreserved Arterial Allograft Reconstruction After Excision of Thoracic Malignancies

Abel Gómez-Caro, MDa, Elisabeth Martinez, MDa, Alberto Rodríguez, MDa, David Sanchez, MDa, Jaume Martorell, MD, PhDb, Josep Maria Gimferrer, MDa, Axel Haverich, MD, PhDc, Wolfgang Harringer, MD, PhDd, Jose Louis Pomar, MD, PhDa, Paolo Macchiarini, MD, PhDa,*

a Department of General Thoracic Surgery, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain
b Department of Immunology, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain
c Department of Cardiothoracic and Vascular Surgery, Hannover Medical School, Hannover, Germany
d Department of Cardiothoracic and Vascular Surgery, Klinikum Braunschweig, Braunschweig, Germany

Accepted for publication June 9, 2008.

* Address correspondence to Dr Macchiarini, Department of General Thoracic Surgery, Hospital Clinic of Barcelona, University of Barcelona, 170 Villaroel, Barcelona, E-30889, Spain (Email: pmacchiarini{at}clinic.ub.es).

Presented at the Forty-fourth Annual Meeting of The Society of Thoracic Surgeons, Fort Lauderdale, FL, Jan 28–30, 2008.

Background: The purpose of this study was to evaluate the long-term clinical and immunologic outcome of cryopreserved arterial allograft (CAA) revascularization of intrathoracic vessels invaded by malignancies.

Methods: Since January 2002, consecutive patients whose intrathoracic vessels were invaded by malignancies were operated on and revascularizion made using human lymphocyte antigen (HLA)– and ABO-mismatched CAAs. Immunologic studies were performed preoperatively, and 1, 3, 6, 12, and 24 months postoperatively. Postoperative oral anticoagulation therapy was not given.

Results: Twenty-six patients aged 53.1 ± 15 years with a nonsmall-cell lung cancer (n = 10), invasive mediastinal tumors (n = 7), pulmonary artery sarcoma (n = 3), laryngeal (n = 2), or other rare lung neoplasms (n = 4) underwent operation. Cardiopulmonary bypass was used in 10 cases (38%), and all resections were pathologically complete. Revascularization was either for venous (n = 12) or arterial (n = 14) vessels, and a total of 30 allografts revascularized the superior vena cava (n = 6), pulmonary artery (n = 7), innominate vein (n = 3) or artery (n = 2), ascendent (n = 4) or descending (n = 1) aorta, and subclavian vein (n = 3) or artery (n = 4). Hospital morbidity and mortality were 50% (n = 13) and 3.8% (n = 1), respectively, all CAA unrelated. With a median follow-up of 18 months (range, 3 to 60+), 5-year survival and allograft patency were 84% and 95%, respectively. Preoperative anti-HLA antibodies were detected in 2 patients (7.7%) and a postoperative anti-HLA antibody response, clinically irrelevant, in 1 of 24 patients (4%).

Conclusions: Revascularization of intrathoracic venous and arterial vessels in patients with malignancies using HLA- and ABO-mismatched CAA is technically feasible and clinically attractive because of no infection risk and postoperative anticoagulation, and excellent long-term survival, patency, and nonimmunogeneicity.




This article has been cited by other articles:


Home page
Ann. Thorac. Surg.Home page
M. Lanuti, P. E. De Delva, H. A. Gaissert, C. D. Wright, J. C. Wain, J. S. Allan, D. M. Donahue, and D. J. Mathisen
Review of superior vena cava resection in the management of benign disease and pulmonary or mediastinal malignancies.
Ann. Thorac. Surg., August 1, 2009; 88(2): 392 - 397.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2008 by The Society of Thoracic Surgeons.